Donglu Zhang

Donglu Zhang

Company: Genentech

Job title: Principal Scientist


Donglu Zhang is interested in applying drug metabolism studies in drug design and development of both small molecule drugs and antibody-drug conjugates (ADCs). He received the Sir James Black Award for discovery of and original research on Eliquis from British Pharmacological Society (2018) and the Ondetti and Cushman Award for invention of mass defect filtering method (MDF) from Bristol-Myers Squibb (2007). He is on Editorial Board of Drug Metabolism and Disposition and Xenobiotica. He edited two textbooks ‘Drug metabolism in drug design and development’, and ‘ADME-enabling technologies in drug design and development’. He received a Ph.D. in Organic Chemistry from University of Utah. 

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.